Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

KLRA

Kailera Therapeutics, Inc.

COMMON STOCK · NASDAQ

Price and daily changeSign in

Earnings11 Nov 2026

52-week rangeSign in

Loading evidence for KLRA

Day range

Market cap: Sign in
Volume: Sign in
Beta: Sign in
Shares float: Sign in
Short interest: 4.37%
P/E (fwd): Sign in
PEG (fwd): Sign in
Rev growth (fwd): Sign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2026-08-06 · filed common shares: 129.64M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.03%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 4.37%
Short ratioDays to cover, as published by FINRA: 6.46
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 59.90%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 50.60%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equity: —
Return on assets: —

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPS (diluted, quarter)Quarter: 2026-04-01 to 2026-06-30 · Not annualized

-1.09

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $130.30M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $10.21M
Debt / equityas of Jun 26: 0.91%
Current ratioas of Jun 26: 11.11
Quick ratio: —
Operating cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$145.83M
Free cash flow (six months)Six months: 2026-01-01 to 2026-06-30 · Not annualized: -$145.83M
TTM revenue / diluted share: —

KLRA stock Statistics — Kailera Therapeutics, Inc. filings, insiders & smart money · Instaport